BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32639951)

  • 1. An individualized transcriptional signature to predict the epithelial-mesenchymal transition based on relative expression ordering.
    Chen T; Zhao Z; Chen B; Wang Y; Yang F; Wang C; Dong Q; Liu Y; Liang H; Zhao W; Qi L; Xu Y; Gu Y
    Aging (Albany NY); 2020 Jul; 12(13):13172-13186. PubMed ID: 32639951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.
    Tan TZ; Miow QH; Miki Y; Noda T; Mori S; Huang RY; Thiery JP
    EMBO Mol Med; 2014 Oct; 6(10):1279-93. PubMed ID: 25214461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
    Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
    Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
    Li Q; Xiao X; Feng J; Yan R; Xi J
    Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma.
    Jung AR; Jung CH; Noh JK; Lee YC; Eun YG
    Sci Rep; 2020 Feb; 10(1):3652. PubMed ID: 32107458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in Kidney Cancer.
    Liang J; Liu Z; Zou Z; Tang Y; Zhou C; Yang J; Wei X; Lu Y
    Sci Rep; 2018 Apr; 8(1):6570. PubMed ID: 29700419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
    Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.
    Yeung TL; Leung CS; Wong KK; Gutierrez-Hartmann A; Kwong J; Gershenson DM; Mok SC
    Oncotarget; 2017 Mar; 8(10):16951-16963. PubMed ID: 28199976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative gene co-expression network analysis of epithelial to mesenchymal transition reveals lung cancer progression stages.
    Wang D; Haley JD; Thompson P
    BMC Cancer; 2017 Dec; 17(1):830. PubMed ID: 29212455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.
    Lutgendorf SK; Penedo F; Goodheart MJ; Dahmoush L; Arevalo JMG; Thaker PH; Slavich GM; Sood AK; Cole SW
    Cancer; 2020 Oct; 126(19):4407-4413. PubMed ID: 32691853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers.
    Yi BR; Kim TH; Kim YS; Choi KC
    Int J Oncol; 2015 Jan; 46(1):272-80. PubMed ID: 25310727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120).
    Huang RY; Kuay KT; Tan TZ; Asad M; Tang HM; Ng AH; Ye J; Chung VY; Thiery JP
    Oncotarget; 2015 Sep; 6(26):22098-113. PubMed ID: 26061747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome profiling reveals novel gene expression signatures and regulating transcription factors of TGFβ-induced epithelial-to-mesenchymal transition.
    Du L; Yamamoto S; Burnette BL; Huang D; Gao K; Jamshidi N; Kuo MD
    Cancer Med; 2016 Aug; 5(8):1962-72. PubMed ID: 27318801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.
    Parsana P; Amend SR; Hernandez J; Pienta KJ; Battle A
    BMC Cancer; 2017 Jun; 17(1):447. PubMed ID: 28651527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
    Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
    Front Immunol; 2022; 13():954616. PubMed ID: 35958586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of 9-Gene Epithelial-Mesenchymal Transition Related Signature of Osteosarcoma by Integrating Multi Cohorts.
    Yiqi Z; Ziyun L; Qin F; Xingli W; Liyu Y
    Technol Cancer Res Treat; 2020; 19():1533033820980769. PubMed ID: 33308057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
    Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.